<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259035</url>
  </required_header>
  <id_info>
    <org_study_id>CO28</org_study_id>
    <nct_id>NCT03259035</nct_id>
  </id_info>
  <brief_title>NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer</brief_title>
  <official_title>NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effects of chemotherapy followed by less&#xD;
      invasive surgery on patients and their early rectal cancer. The approach of this trial will&#xD;
      be considered a success if at least 65% of participants are able to keep the rectum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Anticipated">November 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a two staged, single arm phase II trial of chemotherapy (FOLFOX or CAPOX) followed by tumour excision in patients with early stage rectal cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of organ preservation rate</measure>
    <time_frame>3 years</time_frame>
    <description>The primary endpoint of this study is the protocol specified organ preservation rate, defined as the proportion of patients with tumour downstaging to ypT0/T1good N0 and who avoid radical surgery. The 95% confidence interval for the organ preservation rate will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse Rate (LRR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Relapse Rate (DRR) estimated based on Kaplan-Meier method</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) estimated based on Kaplan-Meier method</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-operative complications</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events using CTCAE V5</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using QLQ-C30</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness using the EQ-5D-5L questionnaire</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy (FOLFOX or CAPOX) followed by tumour excision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfox Protocol</intervention_name>
    <description>6 cycles of q2weekly FOLFOX, or</description>
    <arm_group_label>chemotherapy (FOLFOX or CAPOX) followed by tumour excision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capox</intervention_name>
    <description>4 cycles of q3weekly CAPOX</description>
    <arm_group_label>chemotherapy (FOLFOX or CAPOX) followed by tumour excision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed invasive well-moderately differentiated rectal adenocarcinoma&#xD;
             diagnosed within 90 days prior to enrollment.&#xD;
&#xD;
          -  Tumour stage cT1-T3abN0 based on pelvic MRI&#xD;
&#xD;
               -  cT1N0- tumour invasion into submucosa, no radiographic evidence of mesorectal&#xD;
                  nodal metastasis, tumour deposits or vascular invasion.&#xD;
&#xD;
               -  cT2N0 - tumour invasion into muscularis propria, no radiographic evidence of&#xD;
                  mesorectal nodal metastasis, tumour deposits or vascular invasion.&#xD;
&#xD;
               -  cT3a,bN0- tumour invasion through the muscularis propria no more than 5 mm into&#xD;
                  the subserosa/perirectal tissue and clear of the circumferential radial margin&#xD;
                  (CRM). Absence of radiographic evidence of mesorectal nodal metastasis, tumour&#xD;
                  deposits or lymphovascular invasion.&#xD;
&#xD;
        Note: If the tumour is not visualized in the MRI but there is histological confirmation of&#xD;
        rectal adenocarcinoma the patient is eligible.&#xD;
&#xD;
          -  cN0 stage based on pelvic MRI. Any nodes ≥ 10 mm in longest dimension are considered&#xD;
             malignant, regardless of nodal morphology. For pelvic nodes &lt; 10 mm in longest&#xD;
             dimension, if nodes are seen and are deemed to be morphologically benign in the&#xD;
             opinion of the radiologist and surgeon, the patient is eligible. Patients with visible&#xD;
             pelvic sidewall nodes are excluded&#xD;
&#xD;
          -  M0 stage based on no evidence of metastatic disease by CT imaging.&#xD;
&#xD;
          -  Mid to low-lying tumour eligible for local tumour excision in the opinion of the&#xD;
             treating surgeon.&#xD;
&#xD;
          -  Age of at least 18 years.&#xD;
&#xD;
          -  Medically fit to undergo radical surgery as per treating surgeon's discretion&#xD;
&#xD;
          -  No contraindications to protocol chemotherapy.&#xD;
&#xD;
          -  Adequate normal organ and marrow function as defined below (must be done within 30&#xD;
             days prior to enrolment):&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109/L&#xD;
&#xD;
               -  platelet count ≥100 x 109/L&#xD;
&#xD;
               -  bilirubin &lt; 1.5 ULN, excluding Gilbert's syndrome&#xD;
&#xD;
               -  Calculated creatinine clearance of ≥ 50 ml/min.&#xD;
&#xD;
               -  Clearance to be calculated using Cockcroft formula: Males: 1.23 x (140 - age) x&#xD;
                  weight (kg) - serum creatinine (μmol/l) ; Females: 1.05 x (140 - age) x weight&#xD;
                  (kg) - serum creatinine (μmol/l)&#xD;
&#xD;
          -  The patient must have an ECOG performance status of 0, 1.&#xD;
&#xD;
          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life&#xD;
             and health utility questionnaires.&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements. Each patient must sign a consent form prior to enrollment in&#xD;
             the trial to document their willingness to participate.&#xD;
&#xD;
          -  Must be accessible for treatment and follow up. Patients registered on this trial must&#xD;
             be treated with chemotherapy and followed at the enrolling centre.&#xD;
&#xD;
          -  Protocol treatment is to begin within 5 working days of patient enrollment.&#xD;
&#xD;
          -  Women/men of childbearing potential must have agreed to use a highly effective&#xD;
             contraceptive method during and for 6 months after completion of chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has pathologic high risk factors on either the initial biopsy specimen report&#xD;
             or follow-up biopsy (if done): high histologic grade, mucinous histology, lymphatic or&#xD;
             vascular invasion.&#xD;
&#xD;
          -  History of other malignancies, except: adequately treated non-melanoma skin cancer,&#xD;
             curatively treated in-situ cancer of the cervix, or other solid tumours curatively&#xD;
             treated with no evidence of disease for ≥ 5 years.&#xD;
&#xD;
          -  Synchronous cancer.&#xD;
&#xD;
          -  Prior treatment for rectal cancer.&#xD;
&#xD;
          -  Previous pelvic radiation for any reason.&#xD;
&#xD;
          -  Patients with known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Treatment with other investigational drugs or anti-cancer therapy within 28 days prior&#xD;
             to enrolment.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease for example cerebro&#xD;
             vascular accidents (&lt; 6 months prior to enrolment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrolment), unstable angina, New York Heart Association (NYHA) grade II or&#xD;
             higher, congestive heart failure, serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          -  Any contra-indications to undergo MRI imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagen Kennecke</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Mason Medical Centre, WA USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Brown</last_name>
    <role>Study Chair</role>
    <affiliation>St. Paul's Hospital, Vancouver BC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>97101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

